MGX

0.56507.95%
ML

Matthew L. Wein

Gen­er­al Coun­sel, Com­pli­ance Offi­cer, Head of BD&L and Cor­po­rate Secretary

Mr. Matthew L. Wein, J.D., serves as General Counsel and Head of BD&L at Metagenomi Therapeutics, Inc. since November 2025. He served as Vice President of Corporate Legal and Compliance at Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) since February 2024 until February 2025 and serves as its Corporate Secretary since February 2024. He served as its Senior Vice President, Head of Legal, Compliance Officer at Metagenomi Therapeutics, Inc. since February 2025 and serves as its Compliance Officer since February 2025. Most recently, Mr. Wein served as General Counsel and Corporate Secretary of Mustang Bio, Inc. (Nasdaq: MBIO) from September 2021 to December 2023. Prior to Mustang, Mr. Wein held various roles as Senior Director in global strategy and alliance management for Sanofi between June 2016 and August 2021; and as Senior Counsel at Amgen Inc. (Nasdaq: AMGN) from September 2002 to May 2016. Mr. Wein was an associate attorney at Arter & Haden LLP from August 1999 to August 2002. Mr. Wein received his B.A. from Wesleyan University and his J.D. from University of Southern California Law School. Mr. Wein is admitted to practice law in California and Massachusetts.

Positions